GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib
Regorafenib delayed progression by almost four months compared with placebo in gastrointestinal stromal tumours resistant to both imatinib and sunitinib, giving patients a third line of targeted therapy.
Overview
Phase 3 placebo-controlled trial of 199 patients with metastatic or unresectable GIST after failure of imatinib and sunitinib randomised 2:1 to regorafenib 160 mg daily (three weeks on, one off) or placebo with crossover at progression.
Median progression-free survival was 4.8 versus 0.9 months (hazard ratio 0.27) with disease control in 53 versus 9 percent; hypertension, hand-foot skin reaction and diarrhoea were the main toxicities.
- Median progression-free survival 4.8 vs 0.9 months; hazard ratio 0.27.
- Disease control rate 52.6 percent vs 9.1 percent.
Regorafenib is the standard third-line treatment for GIST after imatinib and sunitinib.
- No overall survival benefit because of crossover.
- Dose reductions needed in most patients.
Similar pages
not linked directly; found by shared links- Key paperSunitinib in advanced gastrointestinal stromal tumour after failure of imatinib
Shares Imatinib-resistant GIST, Sunitinib, The Lancet, Imatinib.
- Key paperINTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
- TrialA Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Shares Imatinib-resistant GIST, Sunitinib.
- Key paperPAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma
Shares Sunitinib, The Lancet.
- TargetPDGFRB
- TermSDH deficiency (SDHB immunohistochemistry loss)
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
- TermGIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)
Shares Imatinib-resistant GIST, Imatinib.
- CancerKIT exon 11-mutant GIST
Shares Regorafenib, Sunitinib, Imatinib.